Aurobindo Pharma Under Pressure as FDA Issues OAI Status

Introduction

Aurobindo Pharma is facing renewed regulatory pressure after the United States Food and Drug Administration (US FDA) classified its Eugia Pharma Specialities Unit-II as 'Official Action Indicated' (OAI). This development, reported on March 17, 2026, signals that the US regulator may take further administrative or regulatory action. The OAI status follows a series of inspections and observations across several of the company's facilities, placing its manufacturing compliance under intense scrutiny and impacting investor sentiment.

A Pattern of Regulatory Hurdles

The OAI classification for Eugia Unit-II is not an isolated incident. Over the past two years, Aurobindo Pharma and its subsidiaries have been subject to multiple US FDA inspections, resulting in a series of observations and warning letters. This pattern has created uncertainty around the company's ability to secure timely approvals for new products from these sites. The consistent regulatory attention highlights ongoing challenges in maintaining compliance with stringent US manufacturing standards.

In February 2026, Eugia Pharma's Unit-III in Telangana was inspected and received 11 observations. The company described these as procedural, but the outcome was seen as a setback, delaying the resolution of issues at a key facility. While existing products from the plant are not affected, the observations restrict future approvals, a crucial element for growth. Similarly, in February 2025, an inspection at Eugia Steriles resulted in five observations, triggering a sharp 9.5% drop in the company's stock price.

Key FDA Actions at Aurobindo Facilities

Impact on Market and Stock Performance

Regulatory news from the US FDA has consistently influenced Aurobindo Pharma's stock performance. The announcement of five observations at its Eugia Steriles facility in February 2025 caused the stock to fall by 9.5% to ₹1,053 per share. The more recent news of 11 observations at Eugia Unit-III in February 2026 had a more moderate impact, with the stock trading around ₹1,195. As of March 17, 2026, the stock closed at ₹1,286, showing an 8.71% gain since the start of the year, suggesting that investors may have priced in some of the regulatory risks. However, the new OAI status for Unit-II introduces fresh concerns that could weigh on the stock's trajectory.

Financial Health Amidst Scrutiny

Despite the regulatory headwinds, Aurobindo Pharma's financial performance has shown resilience, driven by steady demand in key markets. In its third-quarter results for FY25, the company reported an 8.5% year-on-year increase in revenue to ₹79.78 billion. However, its operating performance was subdued, with EBITDA declining 1.5% to ₹16.27 billion and net profit falling 9.7% to ₹8.45 billion. This indicates that while sales remain strong, operational challenges and compliance costs may be impacting profitability. The United States remains the company's largest market, contributing 46.5% of its net sales, making FDA compliance critically important.

Analyst Commentary and Outlook

Analysts view the resolution of FDA issues, particularly at the Eugia facilities, as a key determinant for the company's future. BNP Paribas India, despite noting the negative outcome of the Eugia III inspection, maintained an 'outperform' rating with a target price of ₹1,480 per share. The brokerage firm highlighted Aurobindo's solid base in the US generics market, with 690 approved Abbreviated New Drug Applications (ANDAs) as of FY25, and a well-diversified product portfolio. The company's investments in complex areas like biosimilars and its expansion into the Chinese market are expected to be long-term growth drivers, with commercialization anticipated between FY26 and FY28. However, the immediate focus remains on resolving the compliance gaps identified by the FDA.

Conclusion

Aurobindo Pharma is at a critical juncture. The 'Official Action Indicated' status for its Eugia Unit-II facility underscores the persistent regulatory challenges it faces with the US FDA. While the company's revenue growth remains intact, the repeated observations and warnings across its manufacturing sites pose a significant risk to future product approvals and could impact its growth momentum in the crucial US market. The management's ability to effectively address these compliance issues and restore the FDA's confidence will be paramount in navigating this period of scrutiny and unlocking the company's long-term value.